The future of biologic agents in the treatment of Sjogren's syndrome

Jiska M. Meijer; Justin Pijpe; Hendrika Bootsma; Arjan Vissink; Cees G. M. Kallenberg

doi:10.1007/s12016-007-8005-6

The future of biologic agents in the treatment of Sjogren's syndrome

Jiska M. Meijer^*, Justin Pijpe, Hendrika Bootsma, Arjan Vissink, Cees G. M. Kallenberg

^*Corresponding author voor dit werk

Onderzoeksoutput › peer review

32 Citaten (Scopus)

Samenvatting

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

Originele taal-2	English
Pagina's (van-tot)	292-297
Aantal pagina's	6
Tijdschrift	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume	32
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1007/s12016-007-8005-6
Status	Published - jun.-2007

Toegang tot document

10.1007/s12016-007-8005-6

Handle.net

Permanente koppeling

Citeer dit

@article{3be860041dc245acb6763632827e286d,

title = "The future of biologic agents in the treatment of Sjogren's syndrome",

abstract = "The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.",

keywords = "Sjogren's syndrome, biological agent, treatment, monoclonal antibody, therapy, autoimmune disease, SYSTEMIC AUTOIMMUNE-DISEASES, RHEUMATOID-ARTHRITIS, MONOCLONAL-ANTIBODY, SPECIAL EMPHASIS, CLINICAL-TRIAL, DOUBLE-BLIND, PHASE-I/II, RITUXIMAB, EFFICACY, BAFF",

author = "Meijer, {Jiska M.} and Justin Pijpe and Hendrika Bootsma and Arjan Vissink and Kallenberg, {Cees G. M.}",

year = "2007",

month = jun,

doi = "10.1007/s12016-007-8005-6",

language = "English",

volume = "32",

pages = "292--297",

journal = "CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY",

issn = "1080-0549",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - The future of biologic agents in the treatment of Sjogren's syndrome

AU - Meijer, Jiska M.

AU - Pijpe, Justin

AU - Bootsma, Hendrika

AU - Vissink, Arjan

AU - Kallenberg, Cees G. M.

PY - 2007/6

Y1 - 2007/6

N2 - The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

AB - The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

KW - Sjogren's syndrome

KW - biological agent

KW - treatment

KW - monoclonal antibody

KW - therapy

KW - autoimmune disease

KW - SYSTEMIC AUTOIMMUNE-DISEASES

KW - RHEUMATOID-ARTHRITIS

KW - MONOCLONAL-ANTIBODY

KW - SPECIAL EMPHASIS

KW - CLINICAL-TRIAL

KW - DOUBLE-BLIND

KW - PHASE-I/II

KW - RITUXIMAB

KW - EFFICACY

KW - BAFF

U2 - 10.1007/s12016-007-8005-6

DO - 10.1007/s12016-007-8005-6

M3 - Review article

SN - 1080-0549

VL - 32

SP - 292

EP - 297

JO - CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

JF - CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

IS - 3

ER -

The future of biologic agents in the treatment of Sjogren's syndrome

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit